Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ EVOK opened at $2.82 on Thursday. The firm has a market capitalization of $4.21 million, a price-to-earnings ratio of -0.26 and a beta of 0.12. Evoke Pharma has a one year low of $2.50 and a one year high of $12.32. The company’s 50 day moving average price is $4.40 and its 200 day moving average price is $4.67.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The business had revenue of $3.31 million during the quarter, compared to analyst estimates of $3.08 million.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.